Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lowe`s Companies Inc (LOW) vs Viatris Inc (VTRS) Price & Performance

Lowe`s Companies IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Lowe`s Companies Inc vs Viatris Inc — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Lowe`s Companies Inc is far larger — about 5.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Viatris Inc for 57 Days on average.

LOWVTRS
Market Cap
$105.96B$20.03B
Volume
4,039,54714,109,977
Sector
Consumer CyclicalHealth
52-Week High
$287.39$18.27
52-Week Low
$179.50$9.74
Typical Hold Time
98 Days57 Days
Enterprise Value
$144.81B$32.15B
Dividend Yield
2.65%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lowe`s Companies Inc

Lowe's (LOW) trades at $188.85, up 4.03% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.35% net margins and reasonable valuation at 15.96 P/E. Recent drone delivery innovation with DoorDash and Alphabet demonstrates operational adaptation amid challenging home improvement market conditions.

Outlook remains cautious with housing market headwinds, though analyst consensus targets $244.09 (29% upside). Key risks include interest rate sensitivity and competitive pressure from Home Depot. The company's Dividend King status and consistent cash flow generation provide stability for long-term investors.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LOW
2% Buy98% Sell
Avg holding period · 98 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Lowe`s Companies Inc

Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.

Read more on LOW →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →